Member Info for Livedataaccount

It's ridulous there needs to be an update on tnbc progress i find it unacceptable avacta update please thank you

Like timster says its data for 1a that is being presented 1b is next year

And get a better deal when it comes to deals and financing as the company will negotiate from a higher market cap

It baffles me why there has not been an update on tnbc so far if responses have been seen it's exactly that kind of update that will accelerate the share price

What interview

I would like an update on financing after 4 years in thr clinic surely a deal can be done soon avacta

Wyndrum aggressive bullying and abuse will not be tolerated can you refrain from this immediately

Any chartists out there seems like a good turnaround in the sp last few days

Karen has been key to the turnaround of avacta she has done a fantastic job so far well done karen

Karen is very efficient you can that by looking at her guys

I would also like a full update on what the new cmo is doing maybe a spotlight video and also the deal maker what's he's doing thank you

I would like a full update on Phase 1b progress please. Eager to hear more about tnbc progress

They haven't received the shares yet

I really would like an update on tnbc and what the results are so far.

Does this mean he is likely to depart avacta don't make me ask grok please

Grok on this:

The PubChem entry for substance SID 518168708, named "Ava-6000", is a recent addition (created and modified on August 26, 2025) to the National Institutes of Health's public chemical database.9d4596 This entry links to the standardized compound record (CID 118584251), which includes the molecular formula C41H44N4O14, a 2D structure, and a description noting its role as a fibroblast activation protein (FAP)-activated prodrug of doxorubicin designed to target tumors while reducing systemic toxicities.48fe4aa1b30f The compound is also cross-referenced in other governmental databases like NCATS Inxight Drugs (under UNII 7XPB9B6MUA) and precisionFDA, where it's listed as AVA-6000 or AVA6000, with details on its structure, clinical trial associations, and pharmacological properties as a FAP-activated doxorubicin prodrug.ec863eaaf17336647f

For Avacta PLC, the UK-based biotechnology company developing AVA6000 as its lead pre|CISION™ platform candidate, this PubChem listing is significant as it represents official recognition and curation of the compound's identity from authoritative governmental sources (e.g., NIH or FDA-related entities).2f68479a7213 AVA6000 is an investigational therapy in Phase 1 trials for FAP-positive solid tumors, showing promising early efficacy (e.g., tumor shrinkage and disease control rates over 90% in salivary gland cancers) and a favorable safety profile compared to standard doxorubicin, with reduced cardiac, hematologic, and gastrointestinal toxicities.4afeb35005e3628aa17763a2 The recent PubChem entry, part of a special collection for synonyms from reliable sources, formalizes "Ava-6000" as a standardized name, which can enhance the drug's visibility in scientific literature, support patent and intellectual property claims, and facilitate collaborations or further research.073841

More broadly, such database inclusions often align with regulatory milestones. AVA6000 already holds FDA Orphan Drug Designation (ODD) for soft tissue sarcoma since 2022, providing benefits like 7 years of market exclusivity upon approval, tax credits, and user fee waivers.d3db8b501aad6a5027 Recent company updates indicate an additional ODD for salivary gland cancer (an orphan indication with no approved therapies), which could accelerate approval paths, enable orphan pricing, and avoid certain pricing regulations under the Inflation Reduction Act.39ef616f4f0eda7c61 The timing of the PubChem entry (late August 2025) may reflect updates tied to this progress, as governmental databases like PubChem often incorporate new data following regulatory actions. This boosts Avacta's stock value potential, de-risks the program, and positions AVA6000 for Phase 2/3 trials, potential launches in niche markets like salivary gland cancer by 2028-2029, and expansion to broader indications (e.g., triple-negative breast cancer), targeting a market where FAP is expressed in ~90% of solid tumors.c7aa91

Grok is very good doesnt even sound like ai

Any update from across the pond?

Pleased with the update. To postpone those bond repayments shows a huge amount of confidence from the bond holder and we can assume tnbc is showing efficacy in Phase 1b well done avacta

Is this golden cross?